Analysis of baseline visits that occurred during trimester 1 (n=32)
| Marker | APO (n=14) | PE at any time (n=11) | Preterm delivery (n=10) | |||
| T-test (p value) | DOR (95% CI) | T-test (p value) | DOR (95% CI) | T-test (p value) | DOR (95% CI) | |
| ECR1 | 0.04 | 18.33 (2.39 to 140.4) | 0.59 | 3.94 (0.63 to 24.78) | <0.001 | 32.00 (2.63 to 389.3) |
| EC4d | 0.40 | 1.19 (0.23 to 6.17) | 0.14 | 5.54 (0.58 to 52.95) | 0.40 | 1.03 (0.15 to 7.23) |
| C3 | 0.79 | 0.43 (0.04 to 4.23) | 0.88 | 0.53 (0.05 to 5.30) | 0.80 | 0.88 (0.08 to 9.38) |
| C4 | 0.10 | 0.67 (0.11 to 4.08) | 0.35 | 0.30 (0.03 to 2.87) | 0.18 | 0.50 (0.05 to 5.15) |
| Anti-dsDNA | 0.52 | 0.39 (0.07 to 2.36) | 0.65 | 0.51 (0.08 to 3.14) | 0.73 | 0.31 (0.03 to 3.18) |
| LAC | NA | 0.81 (0.13 to 5.03) | NA | 2.38 (0.41 to 13.75) | NA | 1.90 (0.26 to 13.87) |
| Anti-PS/PT IgG | 0.23 | 1.80 (0.33 to 9.89) | 0.11 | 5.33 (0.89 to 31.92) | 0.17 | 5.25 (0.71 to 39.03) |
| aCL IgG | 0.52 | 2.28 (0.40 to 12.96) | 0.16 | 7.00 (1.11 to 44.06) | 0.17 | 6.60 (0.86 to 50.54) |
| Anti-β2-GP1 IgG | 0.40 | 1.80 (0.33 to 9.89) | 0.12 | 5.33 (0.89 to 31.92) | 0.20 | 5.25 (0.71 to 39.03) |
DOR and p value determined by t-test for ECR1, EC4d, complement proteins C3 and C4, anti-dsDNA, LAC and antiphospholipid antibodies (anti-PS/PT, aCL and anti-β2-GP1) are reported. LAC results are provided as positive or negative. As the t-test could not be performed for LAC, p values are not reported for LAC (NA) in the table. PE at any time includes the pregnancies that presented with PE before (n=7) and after (n=4) the 36th week of gestation.
aCL, anticardiolipin; anti-dsDNA, anti-double-stranded DNA; anti-PS/PT, antiphosphatidylserine prothrombin complex; anti-β2-GP1, anti-β2 glycoprotein 1; APO, adverse pregnancy outcomes; DOR, diagnostic OR; EC4d, erythrocyte-bound C4d; ECR1, erythrocyte complement receptor 1; LAC, lupus anticoagulant; NA, not available; PE, pre-eclampsia.